Lycera Unlocks Elusive Target, Lands Merck Alliance for $307M
By Catherine Shaffer
Friday, March 4, 2011
Lycera Corp. will partner with Merck and Co. Inc. to develop a new class of drugs that target the T-helper 17 (Th17) cells by means of the retinoic acid-related orphan receptor γt (RORγt) transcription factor. Th17 cells produce the pro-inflammatory molecule IL-17.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.